GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Glucocorticoid-dependent stimulation of adiposity and appetite by a ghrelin mimetic in the rat.
Tung. Y L YL; Hewson. A K AK; Dickson. S L SL
Key Findings
- GHRP‑6 increases overall body weight in rats regardless of adrenal (cortisol) status.
- Extra fat accumulation from GHRP‑6 requires normal glucocorticoid (cortisol) levels.
- The appetite‑stimulating effect of GHRP‑6 is absent in rats lacking cortisol.
Practical Outcomes
- For biohackers using GHRP‑6, expect a rise in appetite and weight. If you want to limit fat gain, managing cortisol (e.g., stress reduction or timing with cortisol‑lowering strategies) might help. However, because humans always have some cortisol, the risk of added fat is likely, so monitor diet and consider combining GHRP‑6 with interventions that control cortisol or calorie intake.
Summary
In rats, daily injections of the ghrelin‑like peptide GHRP‑6 made the animals gain weight. The weight gain happened even without the stress hormone cortisol, but the extra body fat only appeared when normal cortisol levels were present. GHRP‑6 also made the rats eat more, but that appetite boost only occurred if cortisol was around.
Abstract
Chronic administration of GH secretagogues (GHSs) induces a state of positive energy balance in rodents by a GH-independent mechanism. Here we sought to determine to what extent the GHS effects to increase food intake and increase fat accumulation are glucocorticoid-dependent. The effects of twice-daily s.c. injections of GH-releasing peptide-6 (GHRP-6) (250 microg/kg) for 2 weeks on body weight, food intake and fat pad weight were determined in both adrenalectomised (ADX) rats (with or without basal corticosterone replacement) and adrenal-intact rats. All GHS-injected rats had a significantly increased body weight at the end of 2 weeks of treatment compared with saline controls. However, increased fat accumulation was only seen in adrenal-intact rats, with a 15% increase in s.c. inguinal (P<0.05 vs saline controls) and 20% increase in visceral mesenteric (P<0.05) fat pad weights following GHS treatment. The increased body weight observed in ADX rats following GHS treatment was not due to increased fat mass or increased weight of other organs measured. Food intake was increased for up to 7 h following a single injection of GHRP-6 in both the adrenal-intact (P<0.01) and corticosterone-replacement groups (P<0.05). This stimulating effect on food intake was not observed at any time point in the ADX rats without corticosterone replacement. These data suggest that GHS-induced body weight gain is glucocorticoid-independent. However, basal levels of glucocorticoids are permissive for the GHS-induced increase in food intake whilst activation of the hypothalamo-pituitary-adrenal axis appears to contribute to the GHS-induced accumulation of fat mass.
Study Information
pubmed
2004
10.1530/eje.0.1500905